Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Ota Fuchs
Cardiovascular & Haematological Disorders - Drug Targets (2018) Vol. 19, Iss. 1, pp. 51-78
Closed Access | Times Cited: 22

Showing 22 citing articles:

Control of human toxoplasmosis
Nicholas C. Smith, Cibelly Goulart, Jenni A. Hayward, et al.
International Journal for Parasitology (2020) Vol. 51, Iss. 2-3, pp. 95-121
Open Access | Times Cited: 207
Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders
Yen-Der Li, W Michelle, Muhammad Murtaza Hassan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 44
Template-assisted covalent modification underlies activity of covalent molecular glues
Yen-Der Li, W Michelle, Muhammad Murtaza Hassan, et al.
Nature Chemical Biology (2024)
Open Access | Times Cited: 16
Topical transdermal administration of lenalidomide nanosuspensions-based hydrogels against melanoma: In vitro and in vivo studies
Meng‐Di Zhang, Haiying Qiu, Zheyi Han, et al.
International Journal of Pharmaceutics X (2025) Vol. 9, pp. 100316-100316
Closed Access | Times Cited: 1
Targeting cereblon in hematologic malignancies
Ota Fuchs
Blood Reviews (2022) Vol. 57, pp. 100994-100994
Open Access | Times Cited: 31
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
Huanjie Yang, Xin Chen, Kai Li, et al.
Seminars in Cancer Biology (2019) Vol. 68, pp. 105-122
Open Access | Times Cited: 46
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Hao Guo, Jingyi Yang, Haoran Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
Lenalidomide attenuates IMQ-induced inflammation in a mouse model of psoriasis
Haiyan Jia, Haiying Qiu, Meng‐Di Zhang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113883-113883
Open Access | Times Cited: 12
Catchet-MS identifies IKZF1-targeting thalidomide analogues as novel HIV-1 latency reversal agents
Enrico Ne, Raquel Crespo, Ray Izquierdo-Lara, et al.
Nucleic Acids Research (2022) Vol. 50, Iss. 10, pp. 5577-5598
Open Access | Times Cited: 9
Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment
Antonio Piccolomo, Claudia Pia Schifone, Vanda Strafella, et al.
Cancers (2020) Vol. 12, Iss. 9, pp. 2528-2528
Open Access | Times Cited: 14
Unlocking the Power of Immune Microenvironment in AML Therapy: Current Insight and Future Prospects
Nurdan Kelesoglu, Kazım Yalçın Arğa
(2024), pp. 131-171
Closed Access | Times Cited: 1
Molecular glue degrader for tumor treatment
Yuhan Hu, Yan Yan, Jiehao Wang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
A sensitive and validated LC-MS/MS method for high-throughput determination of pomalidomide in human plasma and pharmacokinetic studies
Chang Shu, Teng‐Fei Li, Duo Li, et al.
Chinese Chemical Letters (2021) Vol. 33, Iss. 2, pp. 916-919
Closed Access | Times Cited: 8
Reversal of IKZF1-induced glucocorticoid resistance by dual targeting of AKT and ERK signaling pathways
Miriam Butler, Britt M. T. Vervoort, Dorette S. van Ingen Schenau, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 6
Cancer drugs with high repositioning potential for Alzheimer’s disease
Jad Majeed, Marwan N. Sabbagh, Min H. Kang, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 4, pp. 311-332
Closed Access | Times Cited: 2
Molecular modelling assisted design of napthalimide-dihydropyrimidinone conjugates as potential cytotoxic agents
M. Shaheer Malik, Syed Farooq Adil, Zaki S. Seddigi, et al.
Journal of Saudi Chemical Society (2021) Vol. 25, Iss. 5, pp. 101226-101226
Open Access | Times Cited: 5
Immune Response Role of Angiogenesis Inhibitors
John Nemunaitis, Monika Devanaboyina, Nealie Tan Ngo, et al.
Clinical Oncology and Research (2021), pp. 1-13
Open Access | Times Cited: 3
Thionated aminofluorophthalimides reduce classical markers of cellular inflammation in LPS-challenged RAW 264.7 cells
Michael T. Scerba, David Tweedie, Daniela Lecca, et al.
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 76, pp. 128972-128972
Open Access | Times Cited: 2
The dual role of Natural Killer cells during tumor progression and angiogenesis: Implications for tumor microenvironment-targeted immunotherapies
Lorenzo Mortara, Denisa Baci, Grace Coco, et al.
Elsevier eBooks (2021), pp. 305-347
Closed Access | Times Cited: 1
Catchet-MS identifies IKZF1-targeting Thalidomide analogues as novel HIV-1 latency reversal agents
Enrico Ne, Raquel Crespo, Ray Izquierdo-Lara, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 1
Antiangiogenic drugs as chemosensitizers in hematological tumors
Vanessa Desantis, Aurelia Lamanuzzi, Ilaria Saltarella, et al.
Elsevier eBooks (2022), pp. 111-125
Closed Access
dCas9 targeted chromatin and histone enrichment for mass spectrometry (Catchet-MS) identifies IKZF1 as a novel drug-able target for HIV-1 latency reversal
Ne E, Raquel Crespo, Ray Izquierdo-Lara, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access
Page 1

Scroll to top